202 related articles for article (PubMed ID: 33442276)
1. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2021; 13():9-18. PubMed ID: 33442276
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
3. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
[TBL] [Abstract][Full Text] [Related]
5. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
[TBL] [Abstract][Full Text] [Related]
6. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2017; 9():475-483. PubMed ID: 28848355
[TBL] [Abstract][Full Text] [Related]
7. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis of ferric carboxymaltose
Argüelles-Arias F; Bermejo F; Borrás-Blasco J; Domènech E; Sicilia B; Huguet JM; de Arellano AR; Valentine WJ; Hunt B
Therap Adv Gastroenterol; 2022; 15():17562848221086131. PubMed ID: 35574429
[TBL] [Abstract][Full Text] [Related]
9. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
Yun L; YuMei Z; Bn V; Tang Q; Feng C
Cureus; 2023 Nov; 15(11):e48717. PubMed ID: 38094535
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
Pollock RF; Muduma G
Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis.
Kwong WJ; Wang K; Wang P; Boccia R
Drugs Real World Outcomes; 2024 Jun; 11(2):251-261. PubMed ID: 38502304
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
[TBL] [Abstract][Full Text] [Related]
15. Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland.
Aksan A; Schoepfer A; Juillerat P; Vavricka S; Bettencourt M; Ramirez de Arellano A; Gavata S; Morin N; Valentine WJ; Hunt B
Adv Ther; 2021 Jan; 38(1):660-677. PubMed ID: 33216324
[TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease.
Carman N; Muir R; Lewindon P
Transl Pediatr; 2019 Jan; 8(1):28-34. PubMed ID: 30881896
[TBL] [Abstract][Full Text] [Related]
17. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
Kassianides X; Bhandari S
BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
Fukumoto S; Murata T; Osuga Y; Pollock RF
Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
[TBL] [Abstract][Full Text] [Related]
19. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice.
Rieg T; Xue J; Stevens M; Thomas L; White JR; Dominguez Rieg JA
Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37671923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
